Evidence map›Paper›PMID 28440303›Full record

ArticleThe American journal of gastroenterology2017

HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.

Mei-Hsuan Lee, Tiffany I Hsiao, Shreenidhi R Subramaniam, An K Le, Vinh D Vu, Huy N Trinh, Jian Zhang, Mingjuan Jin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review.Journal of clinical and translational hepatology · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 7 countries.

Mei-Hsuan LeeInstitute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Tiffany I HsiaoDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Shreenidhi R SubramaniamInstitute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
An K LeDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Vinh D VuDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Huy N TrinhSan Jose Gastroenterology, San Jose, Califonia, USA.
Jian ZhangChinese Hospital, San Francisco, Califonia, USA.
Mingjuan JinDepartment of Epidemiology and Biostatistics, School of Public Health, Zhejiang University, Hangzhou, China.
Vincent Wai-Sun WongInstitute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Grace Lai-Hung WongInstitute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Mindie H NguyenDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Grace (United States) · USChinese University of Hong Kong · CNIntercept Pharmaceuticals (United States) · USNational Yang Ming University Hospital · TWStanford Medicine · USStanford University · USVirginia Commonwealth University · USZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesHepatitis C virus (HCV) infection is a well-documented risk factor for hepatocellular carcinoma (HCC). Seven HCV genotypes have been classified, and the genotypes show a great variety of geographic distribution. HCV genotype 6 is prevalent in Southeast Asia and has been less studied than the other genotypes.

methodsThis follow-up study was designed to evaluate the natural history of HCV genotype 6. The cohort enrolled 851 Asian patients consisting of 222 with HCV genotype 6 and 629 with other genotypes. The incidence of HCC per 1,000 person-years of various HCV genotypes was estimated by dividing the new HCC cases to the person-years of follow-up. The adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox's proportional hazards models.

resultsAfter 4072 person-years of follow-up, there were 96 newly-developed HCC cases, confirming an incidence of 23.6 per 1000 person-years. By stratifying cirrhosis at study entry, the cumulative risk of HCC among HCV genotype 6 vs. non-6 was 2.9 vs. 2.2% for those without cirrhosis (P=0.45) and 76.2% (95% CI: 55.6-96.8%) vs. 36.2% (95% CI: 28.7-39.1%) for those with cirrhosis (P<0.05), respectively. Among patients with cirrhosis, HCV genotype 6 was significantly associated with HCC compared to patients with non-6 genotypes, with the adjusted HR=2.12 (1.33-3.39), P<0.05. In a model treating patients with genotypes other than 1 or 6 as the reference, the adjusted HR for HCC for HCV genotypes 1 and 6 were 1.13 (0.56-2.27) and 2.34 (1.12-4.86), respectively.

conclusionsAmong patients with cirrhosis, those with HCV genotype 6 infection should be given high priority for antiviral therapy to decrease HCC risk and for vigilant adherence to HCC surveillance.

Indexed as

Carcinoma, HepatocellularDisease ProgressionFemaleGenotypeHepacivirusHepatitis CHong KongHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedRetrospective StudiesRisk Factors

Identifiers

PMID28440303
OpenAlexW2608471646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.